Nathaniel J. Lee

Array ( [id] => 19570350 [patent_doc_number] => 20240374642 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-14 [patent_title] => PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS [patent_app_type] => utility [patent_app_number] => 18/606710 [patent_app_country] => US [patent_app_date] => 2024-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37853 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18606710 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19541721 [patent_doc_number] => 20240358757 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-31 [patent_title] => PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS [patent_app_type] => utility [patent_app_number] => 18/606648 [patent_app_country] => US [patent_app_date] => 2024-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37851 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18606648 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19379313 [patent_doc_number] => 20240269183 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-15 [patent_title] => PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS [patent_app_type] => utility [patent_app_number] => 18/606662 [patent_app_country] => US [patent_app_date] => 2024-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38027 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18606662 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19854459 [patent_doc_number] => 12257269 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-03-25 [patent_title] => Peptides displayed by HLA for use in immunotherapy against different types of cancers [patent_app_type] => utility [patent_app_number] => 18/599838 [patent_app_country] => US [patent_app_date] => 2024-03-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 37840 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18599838 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19947069 [patent_doc_number] => 12318407 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-06-03 [patent_title] => Peptides displayed by HLA for use in immunotherapy against different types of cancers [patent_app_type] => utility [patent_app_number] => 18/599924 [patent_app_country] => US [patent_app_date] => 2024-03-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 34526 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18599924 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19541719 [patent_doc_number] => 20240358755 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-31 [patent_title] => PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS [patent_app_type] => utility [patent_app_number] => 18/599888 [patent_app_country] => US [patent_app_date] => 2024-03-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37842 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18599888 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19430957 [patent_doc_number] => 20240299455 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-12 [patent_title] => PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS [patent_app_type] => utility [patent_app_number] => 18/599860 [patent_app_country] => US [patent_app_date] => 2024-03-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38064 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18599860 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19896822 [patent_doc_number] => 12274716 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-04-15 [patent_title] => Peptides displayed by HLA for use immunotherapy against different types of cancers [patent_app_type] => utility [patent_app_number] => 18/599849 [patent_app_country] => US [patent_app_date] => 2024-03-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 34501 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18599849 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19331293 [patent_doc_number] => 20240245723 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-25 [patent_title] => PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS [patent_app_type] => utility [patent_app_number] => 18/585158 [patent_app_country] => US [patent_app_date] => 2024-02-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37815 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18585158 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19418521 [patent_doc_number] => 20240294644 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-05 [patent_title] => ANTI-VTCN1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES [patent_app_type] => utility [patent_app_number] => 18/425844 [patent_app_country] => US [patent_app_date] => 2024-01-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 67394 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18425844 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19170935 [patent_doc_number] => 20240156909 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-16 [patent_title] => COMPOSITIONS AND METHODS FOR CANCER THERAPY [patent_app_type] => utility [patent_app_number] => 18/417063 [patent_app_country] => US [patent_app_date] => 2024-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22153 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 148 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18417063 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19345247 [patent_doc_number] => 20240254210 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-01 [patent_title] => BRAIN TARGETING COMPOSITIONS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/417787 [patent_app_country] => US [patent_app_date] => 2024-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 75341 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18417787 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19969702 [patent_doc_number] => 12338294 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-06-24 [patent_title] => D-domain containing polypeptides and uses thereof [patent_app_type] => utility [patent_app_number] => 18/486445 [patent_app_country] => US [patent_app_date] => 2023-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 104636 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18486445 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19904171 [patent_doc_number] => 12281167 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-04-22 [patent_title] => Humanized anti-GDNF family alpha-receptor 4 (GRF-alpha-4) antibodies and chimeric antigen receptors (CARs) [patent_app_type] => utility [patent_app_number] => 18/475958 [patent_app_country] => US [patent_app_date] => 2023-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 36 [patent_no_of_words] => 34019 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 189 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18475958 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19067209 [patent_doc_number] => 20240101635 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-28 [patent_title] => ULTRA-LONG ACTING INSULIN-FC FUSION PROTEINS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 18/459581 [patent_app_country] => US [patent_app_date] => 2023-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41162 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18459581 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19318365 [patent_doc_number] => 20240239908 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-18 [patent_title] => ANTIBODY-CONJUGATED NANOPARTICLES AND MEDICAL USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/238650 [patent_app_country] => US [patent_app_date] => 2023-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5328 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18238650 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19258019 [patent_doc_number] => 12018062 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-06-25 [patent_title] => T cell receptors [patent_app_type] => utility [patent_app_number] => 18/324425 [patent_app_country] => US [patent_app_date] => 2023-05-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 9 [patent_no_of_words] => 14350 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 175 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18324425 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18657737 [patent_doc_number] => 20230303690 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-28 [patent_title] => NOVEL ANTI-LAG3 ANTIBODIES AND METHODS OF MAKING AND USING THE SAME [patent_app_type] => utility [patent_app_number] => 18/324935 [patent_app_country] => US [patent_app_date] => 2023-05-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11310 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18324935 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18902757 [patent_doc_number] => 20240018242 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-18 [patent_title] => METHODS OF TREATING CANCER USING LSD1 INHIBITORS IN COMBINATION WITH IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 18/198404 [patent_app_country] => US [patent_app_date] => 2023-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25289 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18198404 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18752503 [patent_doc_number] => 20230355760 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-09 [patent_title] => MODIFIED CELLS OF LEUKEMIC ORIGIN AND A PD-L1 ANTIBODY FOR ENHANCING THE EFFICACY OF CANCER CELL THERAPY [patent_app_type] => utility [patent_app_number] => 18/119487 [patent_app_country] => US [patent_app_date] => 2023-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10480 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18119487 [rel_patent_id] =>[rel_patent_doc_number] =>)